Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.40 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.40 |
| ▸ | GRB2 | P62993 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580398 | 0.92 | GRB2 (0.44) | ACERENXIAPCMA1DPP4 | |
| SCHEMBL29579416 | 0.89 | CALCRL (0.54) | CMA1CALCRLRAMP1POLB | |
| SCHEMBL31661806 | 0.88 | APLNR (0.47) | ACEGRB2 | |
| SCHEMBL29832826 | 0.88 | PTPN1 (0.43) | ACERENCMA1ITGB1ITGA4 | |
| SCHEMBL29580081 | 0.87 | POLB (0.39) | CMA1DPP4FAPCALCRLRAMP1 | |
| SCHEMBL30139051 | 0.85 | OPRM1 (0.44) | XIAPDPP4PREPFAPCALCRL | |
| SCHEMBL29482768 | 0.85 | ACE (0.54) | ACERENXIAPCMA1DPP4 | |
| SCHEMBL29350341 | 0.85 | ACE (0.54) | ACERENXIAPCMA1DPP4 | |
| SCHEMBL29832765 | 0.84 | PTPN1 (0.42) | CMA1CALCRLRAMP1ITGB1ITGA4 | |
| SCHEMBL30745234 | 0.84 | GRB2 (0.42) | XIAPGRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20220119445-A1 | SYNTHETIC CYCLIC PEPTIDES AND METHODS OF PREPARATION AND USE THEREOF | NATIONAL SCIENCE FOUNDATION | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | VIP, PTMS, IAPP | ACE 515/4885REN 180/4885XIAP 384/4885 |
| US-20220119445-A1 | SYNTHETIC CYCLIC PEPTIDES AND METHODS OF PREPARATION AND USE THEREOF | VIP, PTMS, IAPP | ACE 515/4885REN 180/4885XIAP 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.